PROGNOSTIC MODELS FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A TEN-YEAR SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/df08k472Keywords:
Prognostic models, CLL, predictive performancesAbstract
Background: CLL is the most common malignant neoplasm of aging adults in Western populations. CLL is a hematology malignancy defined by the continuous proliferation of monoclonal B lymphocytes in bone marrow, peripheral blood, and lymphoid organs that have a specific immunophenotype. Clinical outcomes for patients with CLL are heterogeneous, leading to the development of prognostic factors. CLL-IPI is a commonly used tool for predicting outcomes.
The aim: This study aims to determine the prognostic models for CLL.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2014 and 2024 were taken into account. Several different online reference sources, like Pubmed, SAGEPUB, and ScienceDirect, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Results: In the PubMed database, the results of our search brought up 27 articles, whereas the results of our search on SAGEPUB brought up 415 articles, our search on ScienceDirect brought up 742 articles. In the end, we included four research that met the criteria.
Conclusion: In conclusion, of the five models, the CLL-IPI shows the best predictive performances. However, further research is needed.
References
Mukkamalla SKR, Taneja A, Malipeddi D, Master SR. Chronic Lymphocytic Leukemia [Internet]. Statpearls. 2023 [cited 2024 Apr 29]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470433/
Kreuzberger N, Damen JAAG, Trivella M, Estcourt LJ, Aldin A, Umlauff L, et al. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. Vol. 2020, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2020.
Chiorazzi N, Chen SS, Rai KR. Chronic lymphocytic leukemia. Cold Spring Harb Perspect Med. 2021 Feb 1;11(2):1–35.
Condoluci A, Terzi Di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia [Internet]. Vol. 135, Blood. 2020. Available from: http://ashpublications.org/blood/article-pdf/135/21/1859/1731550/bloodbld2019003453.pdf
Alshemmari SH, Alsarraf A, Kunhikrishnan A, Pandita R. Evaluation of the CLL-IPI and IPS-E Prognostic Indices in a Young Middle Eastern Population with Chronic Lymphocytic Leukemia: A Retrospective Analysis at the Kuwait Cancer Control Center. Medical Principles and Practice. 2023 Oct 28;32(3):192–9.
Strati P, Jain N, O’Brien S. Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Vol. 93, Mayo Clinic Proceedings. Elsevier Ltd; 2018. p. 651–64.
Muñoz-Novas C, Poza-Santaella M, González-Gascón Y Marín I, Hernández-Sánchez M, Rodríguez-Vicente AE, Infante MS, et al. The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers only Prognostic Model and the MD Anderson Cancer Center Prognostic Index. Biomed Res Int. 2018;2018.
Pan B, Li Y, Xu Z, Miao Y, Yin H, Kong Y, et al. Identifying a novel ferroptosis-related prognostic score for predicting prognosis in chronic lymphocytic leukemia. Front Immunol. 2022 Oct 6;13.
Xu Z, Pan B, Li Y, Xia Y, Liang J, Kong Y, et al. Identification and Validation of Ferroptosis-Related LncRNAs Signature as a Novel Prognostic Model for Chronic Lymphocytic Leukemia. Int J Gen Med. 2023;16:1541–53.
Liang X, Meng Y, Li C, Liu L, Wang Y, Pu L, et al. Super-Enhancer–Associated nine-gene prognostic score model for prediction of survival in chronic lymphocytic leukemia patients. Front Genet. 2022 Sep 15;13.
Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Vol. 391, The Lancet. Lancet Publishing Group; 2018. p. 1524–37.
Yun X, Zhang Y, Wang X. Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia. Vol. 8, Biomarker Research. BioMed Central Ltd; 2020.
Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Schwager SM, et al. Chronic lymphocytic leukemia in young (55 years) patients: A comprehensive analysis of prognostic factors and outcomes. Haematologica. 2014 Jan 1;99(1):140–7.
Baumann T, Moia R, Gaidano G, Delgado J, Condoluci A, Villamor N, et al. Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients. Leukemia. 2021 Aug 1;35(8):2325–31.
Molica S, Shanafelt TD, Giannarelli D, Gentile M, Mirabelli R, Cutrona G, et al. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. Am J Hematol. 2016 Nov 1;91(11):1090–5.
Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014 Jul 3;124(1):49–62.
Rani L, Gogia A, Singh V, Kumar L, Sharma A, Kaur G, et al. Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort. Ann Hematol. 2019 Feb 4;98(2):437–43.
Gentile M, Shanafelt TD, Mauro FR, Laurenti L, Rossi D, Molica S, et al. Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases. Vol. 93, American Journal of Hematology. Wiley-Liss Inc.; 2018. p. E35–7.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Landong Sijabat, Guinanti Novettiandari
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
